重组人生长激素治疗生长激素缺乏症儿童引发肿瘤相关性的Meta分析

doi:10.11852/zgetbjzz2017-25-01-16

中国儿童保健杂志 ›› 2017, Vol. 25 ›› Issue (1): 55-58.DOI: 10.11852/zgetbjzz2017-25-01-16

重组人生长激素治疗生长激素缺乏症儿童引发肿瘤相关性的Meta分析

李鑫¹,班博²,乔建敏¹,陈汉文³,郑成然¹

1 山东大学医学院,山东济南 250012;
2 济宁医学院附属医院
内分泌科,山东济宁 272029;
3 济宁医学院,山东济宁 272029

收稿日期:2016-05-23 发布日期:2017-01-10 出版日期:2017-01-10
通讯作者: 班博,E-mail:banbo2011@163.com
作者简介:李鑫(1990-),女,山东人,硕士研究生,研究方向为下丘脑-垂体疾病。

Meta-analysis on the association of the relativity of neoplasms and the effect of recombinant human growth hormone therapy in growth hormone deficiency.

LI Xin¹,BAN Bo²,QIAO Jian-min¹,CHEN Han-wen³,ZHENG Cheng-ran¹.

1 Medical College of Shandong University,Jinan,Shandong 250012,China;
2 Department of Endocrinology,Affiliated Hospital of Jining Medical College,Jining,Shandong 272029,China;
3 Jining Medical College,Jining,Shandong 272029,ChinaCorresponding author:BAN Bo,Email:banbo2011@163.com

Received:2016-05-23 Online:2017-01-10 Published:2017-01-10
Contact: BAN Bo,Email:banbo2011@163.com

摘要/Abstract

摘要： 目的系统评价应用重组人生长激素(rhGH)治疗生长激素缺乏症(GHD)儿童后,与肿瘤发生相对危险度、肿瘤死亡率以及再发肿瘤发生相对危险度的相关性。方法计算机检索Pubmed、EMbase、The CNKI、CBM、The Cochrane Library等中英文数据库,搜集有关应用rhGH治疗GHD后与肿瘤相关性的文献。根据Cochrane系统评价方法,进行文献资料收集、质量评价、数据提取,最后采用Revman 5.3软件进行Meta分析。结果最终纳入16篇文献,Meta分析结果显示GHD患儿应用rhGH治疗后,肿瘤的发生风险无增加,两者无相关性(RR=0.76,95%CI为0.59~0.90,P<0.05)。应用rhGH治疗后,GHD组发生肿瘤的死亡率与预期死亡率相比,结果无统计意义,说明rhGH并不增加肿瘤患儿的死亡率(SMR=0.90,95%CI为0.77~1.05,P>0.05)。但是对于既往患有肿瘤的患者,应用rhGH后,可以使再发肿瘤的风险进一步增加,危险性增加1.3倍(RR=2.30,95%CI为1.61~3.27,P<0.05)。结论 GHD患儿应用rhGH治疗后,肿瘤发生相对风险及死亡率无明显增加,但是再发肿瘤的危险性增加1.3倍。

关键词: 重组人生长激素, 安全性, 肿瘤相对危险比, 系统评价

Abstract: Objective To evaluate the effectiveness of recombinant human growth hormone(rhGH) for growth hormone deficiency(GHD)with the relative risk of neoplasms,cancer mortality and the second neoplasms. Methods The research study about the application of recombinant human growth hormone in treating GHD and cancer-related literature searched in Pubmed,EMbase,The CNKI,CBM,the Cochrane Library and so on.According to the Cochrane Handbook,literature was screened,methodological quality assessed,date extrated and meta-analysis conducted using Revman 5.3 software. Results A total of 16 research references were including,the results of meta-analysis showed that the risk of neoplasms in GHD patients treated with rhGH was not higher (RR=0.76,95%CI was 0.59~0.90,P<0.05).Application of rhGH treatment,the overall mean neoplasms standardized mortality ratios(SMR) for treated patients was not significantly increased,and that rhGH did not increase mortality in patients with cancer(SMR=0.90,95%CI was 0.77~1.05,P>0.05).But for patients who previously suffered from cancer,after the application of rhGH,which could further increase neoplasms risk 1.3 times (RR=2.30,95%CI was 1.61~3.27,P<0.05). Conclution The relative risk and the SMR of neoplasms in GHD patients treated with rhGH is not higher,but the second neoplasms risk increases by about 1.3 times.

Key words: recombinant human growth hormone, safety, the relative risk of neoplasms, systematic review

中图分类号:

R179

李鑫,班博,乔建敏,陈汉文,郑成然. 重组人生长激素治疗生长激素缺乏症儿童引发肿瘤相关性的Meta分析[J]. 中国儿童保健杂志, 2017, 25(1): 55-58.

LI Xin,BAN Bo,QIAO Jian-min,CHEN Han-wen,ZHENG Cheng-ran.. Meta-analysis on the association of the relativity of neoplasms and the effect of recombinant human growth hormone therapy in growth hormone deficiency.[J]. journal1, 2017, 25(1): 55-58.

参考文献

[1] 袁意,杨玉.特发性矮小基因研究进展[J].南昌大学学报,2013,53(1):104-106.
[2] Arnold JR,Arnold DF,Marland A,et al.GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence[J].Clinical Endocrinology,2009,70(3):435-438.
[3] Buchfelder M,Kann PH,Wuster C,et al.Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas:a case control study[J].European journal of endocrinology / European Federation of Endocrine Societies,2007,157(2):149-156.
[4] Child CJ,Zimmermann AG,Woodmansee WW,et al.Assessment of primary cancers in GH-treated adult hypopituitary patients:an analysis from the hypopituitary control and complications study[J].European Journal of Endocrinology / European Federation of Endocrine Societies,2011,165(2):217-223.
[5] Hartman ML,Xu R,Crowe BJ,et al.Prospective safety surveillance of GH-deficient adults:comparison of GH-treated vs untreated patients[J].The Journal of Clinical Endocrinology and Metabolism,2013,98(3):980-988.
[6] Hatrick AG,Boghal P,Bingham JB,et al.Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours?[J].European Journal of endocrinology / European Federation of Endocrine Societies,2002,146(6):807-811.
[7] Mackenzie S,Craven T,Gattamaneni HR,et al.Long-term safety of growth hormone replacement after CNS irradiation[J].The Journal of Clinical Endocrinology and Metabolism,2011,96(9):2756-2761.
[8] Olsson DS,Buchfelder M,Schlaffer S,et al.Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy[J].European Journal of Endocrinology / European Federation of Endocrine Societies,2009,161(5):663-669.
[9] Olsson DS,Buchfelder M,Wiendieck K,et al.Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up[J].European Journal of Endocrinology/European Federation of Endocrine Societies,2012,166(6):1061-1068.

[1]	杨婷婷, 李鑫, 俞鑫璐, 张博, 庞伟. 体感游戏对脑瘫儿童上肢功能影响的系统评价[J]. 中国儿童保健杂志, 2023, 31(5): 535-540.
[2]	吕萍萍, 崔乃雪, 韩静, 胡梦珠, 乐蕾, 单瑞洁. 孤独症谱系障碍儿童焦虑评估工具的系统评价[J]. 中国儿童保健杂志, 2022, 30(12): 1358-1363.
[3]	万乃君, 张田, 张金, 孙慧慧, 商然, 师伟佳. 长效重组人生长激素治疗儿童生长激素缺乏症的有效性及安全性研究[J]. 中国儿童保健杂志, 2021, 29(7): 755-758.
[4]	曾佩佩, 黄丽萍, 邓梁琼, 冯玉山, 熊莉, 曾婷, 李红辉. 重组人生长激素治疗对特发性矮小症儿童心理状态影响的分析[J]. 中国儿童保健杂志, 2021, 29(1): 71-74.
[5]	王琳. 新型冠状病毒肺炎流行期间免疫规划疫苗延迟接种安全性[J]. 中国儿童保健杂志, 2020, 28(3): 242-246.
[6]	胡珊珊, 王晓晔, 李争, 陶秀彬. 影响我国母乳喂养持续时间相关因素的系统评价[J]. 中国儿童保健杂志, 2020, 28(10): 1131-1134.
[7]	丁艳华. 儿童早期依恋情感和社会化发展[J]. 中国儿童保健杂志, 2019, 27(9): 932-935.
[8]	彭艳松, 邹芙蓉. 重组人生长激素对青春期前特发性矮身材儿童的生长速率、骨龄的影响及其量效-时效关系[J]. 中国儿童保健杂志, 2019, 27(11): 1228-1231.
[9]	阮敏仪, 饶红萍, 杨勇, 张兰, 苏锦珍, 李敏许. 持续肺充气对早产低出生体重儿呼吸窘迫综合征干预的安全性研究[J]. 中国儿童保健杂志, 2019, 27(10): 1079-1083.
[10]	王昭睿,郝萌萌. 重组人生长激素治疗儿童特发性矮小39例分析[J]. 中国儿童保健杂志, 2017, 25(4): 423-424.
[11]	郑成然,班博,张梅,孙海玲,李萍,王娜,邵倩. 重组人生长激素治疗对生长激素缺乏症患儿甲状腺功能的影响及其临床意义[J]. 中国儿童保健杂志, 2016, 24(6): 616-618.
[12]	潘丹丹,刘建华,鲁承熙,艾戎,童雪涛,刘秀琼. 重组人生长激素治疗青春晚期大骨龄特发性矮小女童必要性研究[J]. 中国儿童保健杂志, 2016, 24(10): 1077-7080.
[13]	郭春艳，贺波，呼延佳，尹春燕，肖延风. 重组人生长激素对身材矮小儿童增高疗效的相关影响因素分析[J]. 中国儿童保健杂志, 2015, 23(2): 147-149.
[14]	尚睿娴, 王争艳, 迟兆艳, 陈文凤. 家访式预防性干预对流动家庭母婴依恋的影响[J]. 中国儿童保健杂志, 2014, 22(9): 1005-1008.
[15]	党桂娟,裴丹. 重组人生长激素治疗儿童特发性矮小症49例分析[J]. 中国儿童保健杂志, 2014, 22(5): 552-553.

重组人生长激素治疗生长激素缺乏症儿童引发肿瘤相关性的Meta分析

Meta-analysis on the association of the relativity of neoplasms and the effect of recombinant human growth hormone therapy in growth hormone deficiency.

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics